Literature DB >> 24799496

Opiate pharmacology and relief of pain.

Gavril W Pasternak1.   

Abstract

Opioids remain the mainstay of severe pain management in patients with cancer. The hallmark of pain management is individualization of therapy. Although almost all clinically used drugs act through mu opioid receptors, they display subtle but important differences pharmacologically. Furthermore, not all patients respond equally well to all drugs. Evidence suggests that these variable responses among patients have a biologic basis and are likely to involve both biased agonism and the many mu opioid receptor subtypes that have been cloned.
© 2014 by American Society of Clinical Oncology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24799496      PMCID: PMC4031189          DOI: 10.1200/JCO.2013.53.1079

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  44 in total

Review 1.  Mu opioids and their receptors: evolution of a concept.

Authors:  Gavril W Pasternak; Ying-Xian Pan
Journal:  Pharmacol Rev       Date:  2013-09-27       Impact factor: 25.468

Review 2.  Functional selectivity at the μ-opioid receptor: implications for understanding opioid analgesia and tolerance.

Authors:  Kirsten M Raehal; Cullen L Schmid; Chad E Groer; Laura M Bohn
Journal:  Pharmacol Rev       Date:  2011-08-26       Impact factor: 25.468

Review 3.  Controlling the pain of cancer.

Authors:  K M Foley
Journal:  Sci Am       Date:  1996-09       Impact factor: 2.142

Review 4.  Efficacy and ligand bias at the μ-opioid receptor.

Authors:  E Kelly
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

Review 5.  The endocrine effects of long-term oral opioid therapy: a case report and review of the literature.

Authors:  Jennifer A Elliott; Erica Horton; Eugene E Fibuch
Journal:  J Opioid Manag       Date:  2011 Mar-Apr

6.  Neuroanatomical correlates of morphine dependence.

Authors:  E Wei; H H Loh; E L Way
Journal:  Science       Date:  1972-08-18       Impact factor: 47.728

7.  Novel receptor mechanisms for heroin and morphine-6 beta-glucuronide analgesia.

Authors:  G C Rossi; G P Brown; L Leventhal; K Yang; G W Pasternak
Journal:  Neurosci Lett       Date:  1996-09-20       Impact factor: 3.046

8.  Peripheral morphine analgesia: synergy with central sites and a target of morphine tolerance.

Authors:  Y A Kolesnikov; S Jain; R Wilson; G W Pasternak
Journal:  J Pharmacol Exp Ther       Date:  1996-11       Impact factor: 4.030

9.  mu opiate receptor: cDNA cloning and expression.

Authors:  J B Wang; Y Imai; C M Eppler; P Gregor; C E Spivak; G R Uhl
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-01       Impact factor: 11.205

10.  Separation of morphine analgesia from physical dependence.

Authors:  G S Ling; J M MacLeod; S Lee; S H Lockhart; G W Pasternak
Journal:  Science       Date:  1984-10-26       Impact factor: 47.728

View more
  21 in total

1.  Abuse Liability, Anti-Nociceptive, and Discriminative Stimulus Properties of IBNtxA.

Authors:  Ariful Islam; Mohammad Atiqur Rahman; Megan B Brenner; Allamar Moore; Alyssa Kellmyer; Harley M Buechler; Frank DiGiorgio; Vincent R Verchio; Laura McCracken; Mousumi Sumi; Robert Hartley; Joseph R Lizza; Gustavo Moura-Letts; Bradford D Fischer; Thomas M Keck
Journal:  ACS Pharmacol Transl Sci       Date:  2020-07-27

Review 2.  Gα(i/o)-coupled receptor-mediated sensitization of adenylyl cyclase: 40 years later.

Authors:  Tarsis F Brust; Jason M Conley; Val J Watts
Journal:  Eur J Pharmacol       Date:  2015-05-14       Impact factor: 4.432

Review 3.  Opioid receptors: Structural and mechanistic insights into pharmacology and signaling.

Authors:  Yi Shang; Marta Filizola
Journal:  Eur J Pharmacol       Date:  2015-05-14       Impact factor: 4.432

4.  Mu Opioid Receptors in Gamma-Aminobutyric Acidergic Forebrain Neurons Moderate Motivation for Heroin and Palatable Food.

Authors:  Pauline Charbogne; Olivier Gardon; Elena Martín-García; Helen L Keyworth; Aya Matsui; Anna E Mechling; Thomas Bienert; Md Taufiq Nasseef; Anne Robé; Luc Moquin; Emmanuel Darcq; Sami Ben Hamida; Patricia Robledo; Audrey Matifas; Katia Befort; Claire Gavériaux-Ruff; Laura-Adela Harsan; Dominik von Elverfeldt; Jurgen Hennig; Alain Gratton; Ian Kitchen; Alexis Bailey; Veronica A Alvarez; Rafael Maldonado; Brigitte L Kieffer
Journal:  Biol Psychiatry       Date:  2016-12-26       Impact factor: 13.382

Review 5.  Biased agonism: An emerging paradigm in GPCR drug discovery.

Authors:  Zoran Rankovic; Tarsis F Brust; Laura M Bohn
Journal:  Bioorg Med Chem Lett       Date:  2015-12-09       Impact factor: 2.823

6.  Ligand-Based Discovery of a New Scaffold for Allosteric Modulation of the μ-Opioid Receptor.

Authors:  Paola Bisignano; Neil T Burford; Yi Shang; Brennica Marlow; Kathryn E Livingston; Abigail M Fenton; Kristin Rockwell; Lauren Budenholzer; John R Traynor; Samuel W Gerritz; Andrew Alt; Marta Filizola
Journal:  J Chem Inf Model       Date:  2015-09-15       Impact factor: 4.956

7.  Mechanism of μ-Opioid Receptor-Magnesium Interaction and Positive Allosteric Modulation.

Authors:  Xiaohu Hu; Davide Provasi; Steven Ramsey; Marta Filizola
Journal:  Biophys J       Date:  2019-10-14       Impact factor: 4.033

8.  Involvement of Mu Opioid Receptor Signaling in the Protective Effect of Opioid against 6-Hydroxydopamine-Induced SH-SY5Y Human Neuroblastoma Cells Apoptosis.

Authors:  Shahrzad Eftekhar-Vaghefi; Saeed Esmaeili-Mahani; Leila Elyasi; Mehdi Abbasnejad
Journal:  Basic Clin Neurosci       Date:  2015-07

Review 9.  Natural Products for the Treatment of Pain: Chemistry and Pharmacology of Salvinorin A, Mitragynine, and Collybolide.

Authors:  Soumen Chakraborty; Susruta Majumdar
Journal:  Biochemistry       Date:  2020-09-22       Impact factor: 3.162

10.  Proposed Mode of Binding and Action of Positive Allosteric Modulators at Opioid Receptors.

Authors:  Yi Shang; Holly R Yeatman; Davide Provasi; Andrew Alt; Arthur Christopoulos; Meritxell Canals; Marta Filizola
Journal:  ACS Chem Biol       Date:  2016-02-17       Impact factor: 5.100

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.